



## Liver Disease and Therapy

Guest Editor:

**Prof. Dr. Nahum Mendez-Sanchez**

1. Fundación Clínica Médica Sur, Ciudad de México, México
2. Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico

Deadline for manuscript submissions:

**closed (31 March 2023)**

### Message from the Guest Editor

According to the global health estimates from 2015 of the World Health Organization, around 1.2 million people worldwide die each year from liver cirrhosis and subsequent complications, while 800,000 die of hepatocellular carcinoma, comprising 3.5% of all deaths worldwide. It has also been suggested that about 296 million people around the world were living with chronic hepatitis B infection in 2019, with 1.5 million new infections each year. In addition, metabolic dysfunction-associated fatty liver disease is the most common liver disease worldwide, affecting a quarter of the global population, and is often associated with adverse health outcomes. Importantly, alcohol-related liver diseases have remained as the major etiology of liver diseases in some European countries for decades. These data emphasize the importance of establishing an adequate standard of care, with the consideration of cirrhosis as a major comorbidity. Management should be focused on the prevention of the recurrence of complications, some of which now involve specific treatment. Therefore, the aim of this Special Issue is to review the current novel treatments for liver disease.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI